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Abstract
Objective. To evaluate the efficacy and safety of three dosing and repeat treatment regimens of rituximab
(RTX) plus MTX in patients with active RA.
Methods. Patients with active RA despite stable MTX (10–25mg/week) were randomly assigned to one of
the three treatment regimens comprising two courses of RTX given 24 weeks apart: 2500 and
2500mg; 2500 and 21000mg (dose escalation); and 21000 and 21000mg. The primary endpoint
was proportion of patients achieving ACR20 at Week 48.
Results. At Week 48, ACR20 responses were not statistically significantly different between the dose
regimens. Compared with RTX 2500mg (n=134) or dose escalation (n=119), ACR and European
League Against Rheumatism (EULAR) outcomes in the RTX 21000mg group (n=93) were consistently
higher, with significantly more patients achieving EULAR responses (P=0.0495). At Week 48, rituximab
21000mg was associated with a higher proportion of patients who, following retreatment, maintained or
improved their Week 24 responses. Dose escalation from 2500 to 21000mg did not appear to be
associated with improved outcomes compared with continual 2500mg. All RTX regimens demonstrated
comparable safety.
Conclusions. RTX 2500 and 21000mg could not be clearly differentiated, although some efficacy
outcomes suggest improved outcomes in the rituximab 21000mg group. Retreatment from Week 24
resulted in a sustained suppression of disease activity through to Week 48.
Trial registration. ClinicalTrials.gov, http://clinicaltrials.gov/, NCT00422383.
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Introduction
Rituximab (RTX), an mAb that selectively targets and de-
pletes CD20
+ B cells, has demonstrated significant effi-
cacy and a favourable safety profile in clinical trials
conducted in patients with active RA [1, 2]. RTX
21000mg in combination with MTX resulted in a signifi-
cant clinical and radiographical benefit in patients with an
inadequate response or intolerance to TNF inhibitors [3],
and this dose or a lower dose of 2500mg resulted
in significant improvements in disease activity in
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DMARDs [4].
Consequently, questions remain, not only regarding the
most appropriate dose of RTX, but also how and when
patients should receive further courses. In long-term ob-
servational studies, patients who had an initial response to
RTX were allowed further courses no more frequently than
every 16 weeks if they had active disease (defined by at
least eight swollen and eight tender joints) [5], with the
decision to retreat also being at the discretion of the treat-
ing physician. As a consequence, at an individual patient
level, repeat treatment times were highly variable, with
clear evidence of returning disease between treatment
courses. While defining a fixed repeat treatment schedule
suitable for all patients may not be appropriate, it would,
however, be desirable to retreat patients before a signifi-
cant clinical flare occurs.
Further, the benefit of repeat treatment in patients in
whom an initial response was not achieved has not been
established and requires further investigation. Similarly,
data on any effect of dose used for such repeat treatments
may provide clinically relevant information.
Therefore, the present study was designed to determine
if initiating treatment with RTX 2500mg followed by a
repeat treatment at 24 weeks with 2500mg was different
from repeat treatment with a higher dose of 21000mg.
The study was also designed to compare the efficacy and
safety of RTX 2500 and 21000mg over 48 weeks with
a fixed repeat treatment at Week 24.
Methods
Study design
This study was a multicentre, randomized, double-blind,
Phase III trial conducted as part of the clinical develop-
ment programme for RTX in patients with an inadequate
response to disease modifying therapies. The study was
conducted at 81 centres in 18 countries in patients
with active RA who had an inadequate clinical response
to MTX therapy. The overall study design is shown
in Fig. 1. Patients were randomly assigned to three
treatment groups: initial treatment with RTX 2500mg
with a repeat course at Week 24 also of 2500mg;
dose escalation (initially RTX 2500mg, with 2
1000mg on retreatment); or initial treatment with rituximab
21000mg and retreatment with 21000mg. All RTX
infusions were preceded by intravenous methylpredniso-
lone 100mg.
The pharmacokinetic profile of RTX shows that by 16–
24 weeks, drug levels are below the level of detection and
there is evidence of gradual repletion of peripheral CD19
+
B cells [6], which in some patients may precede recur-
rence of active disease. Further, evidence suggests that
even low circulating CD19 levels may be associated with
poor response or returning disease [7]. Retreatment at 24
weeks, therefore, represents a reasonable time at which
to retreat.
Patients were randomly allocated using an interactive
voice response system; the randomization was stratified
by region, RF seropositivity and prior biological use.
Although all patients were randomly assigned to
RTX-containing regimens, allocation to dose and repeat
treatment regimen was blinded. The sponsor, investiga-
tors and patients were blinded to the treatment allocation
up to the time of the Week 48 analysis. Treatment assign-
ments were unblinded to the sponsor at this time for the
purpose of the data analysis.
Stable doses of MTX (10–25mg/week) were maintained
throughout the study period. Permitted co-medications
included folic acid (5mg/week) NSAIDs and oral gluco-
corticoids (410mg/day). IA glucocorticoid injections
were restricted to not more than one joint per 24-week
period. Use of additional non-biological and biological
DMARDs was strictly prohibited.
The study was performed in accordance with the
Declaration of Helsinki. All participating sites received
approval from their governing institutional review board
(or equivalent) and all patients provided written informed
consent. The study is registered with ClinicalTrials.gov:
NCT00422383.
Patients
Inclusion criteria included a diagnosis of RA (according to
the revised 1987 ACR criteria for the classification of RA)
for at least 6 months with active disease, despite MTX at
10–25mg/week for 512 weeks (at a stable dose for the
previous 4 weeks). Active disease was defined as swollen
joint count (SJC) 58 (66-joint count) and tender joint
count (TJC) 58 (68-joint count) at screening and baseline,
with CRP56mg/l or ESR528mm/h.
Key exclusion criteria included the earlier receipt of
more than one biological agent approved for use in RA;
significant systemic involvement secondary to RA; a his-
tory of current inflammatory joint disease other than RA or
another systemic autoimmune disorder; significant car-
diac or pulmonary disease; active infection or history of
serious recurrent or chronic infection.
Assessments
The primary endpoint was the proportion of patients with
an ACR20 response at Week 48 [8]. Secondary endpoints
at Week 48 included ACR50 and ACR70 responses;
changes from baseline in disease activity score (DAS-
28-ESR) [9]; European League Against Rheumatism
(EULAR) response [10]; change from baseline in Medical
Outcomes Study Short Form (36-item) Health Survey
(SF-36) subscale and summary scores [11, 12]; and
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) assessment [13]. Exploratory endpoints
included proportion of patients achieving DAS-28-ESR re-
mission, defined as a DAS-28-ESR<2.6 [9], assessment
of function using the HAQ-Disability Index (HAQ-DI) and
the proportion of patients with a minimal clinically import-
ant difference (MCID) in HAQ-DI, defined as an improve-
ment of at least 0.22 [14].
Pharmacodynamic outcomes included peripheral B-cell
and T-cell counts (measured by flow cytometry), immuno-
globulin (Ig) concentrations (including isotypes), presence
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both RF and anti-citrullinated peptide antibodies [by de-
tection of anti-cyclic citrullinated (aCCP) antibodies].
Clinical adverse events (AEs) were recorded throughout
the study and graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAEs), version 3 [15]. Serious AEs (SAEs) were defined
as per the International Conference on Harmonization
(ICH) criteria [16].
Statistical analysis
Randomization was stratified by region, RF (RF
+5
20IU/ml or RF
<20IU/ml) and an earlier biological use.
Seronegative patients and patients with earlier exposure
to biological therapies were limited to not more than
20 and 30% of the total population, respectively.
A sample size of 125 patients per arm (375 patients in
total) was determined to ensure 80% power to discern a
17.5% difference in the proportion of patients with an
ACR20 response at Week 48 between the RTX
2500mg group and the dose escalation treatment
group, using Fisher’s exact test with a two-sided signifi-
cance level of 0.05.
For the primary efficacy variable (ACR20 response at
Week 48), the RTX 2500mg group was compared with
the dose escalation group (the primary analysis) using the
Cochran–Mantel–Haenszel (CMH) test and logistic
regression analysis, adjusted for baseline factors of RF
status, region and earlier biological use. Further explora-
tory analyses were conducted to compare the 2500mg
group with the 21000mg group.
Secondary endpoints were analysed to compare the
2500mg group with the dose escalation group (the
secondary analysis) using the CMH test for categorical
endpoints and analysis of variance (ANOVA) for continuous
endpoints, both adjusted for baseline stratification factors.
ANOVA models also included the baseline value for the
endpoint, if applicable. Missing data were imputed using
the non-responder method for ACR and EULAR (all pa-
tients who withdrew were classed as non-responders);
last observation carried forward was used for all other end-
points. Further exploratory analyses were conducted to
compare the 2500mg group with the 21000mg group.
During the conduct of the study, the sponsor became
aware of treatment errors owing to a lack of synchroniza-
tion between an updated medication list and the random-
ization schedule. These treatment errors affected 60
patients and subsequently potentially compromised any
analysis based on the intent-to-treat population (ITT; all
treated patients as randomized). Results are consequently
presented froma modified ITT (mITT) analysis withpatients
analysed by the treatment they actually received as
opposedtothetreatmenttheywererandomizedtoreceive.
Analyses using the standard (as randomized) ITT popula-
tion were conducted on the primary endpoint (ACR20).
Results
Patient disposition
In total, 378 patients were randomly assigned, with all
except one receiving at least one infusion. The protocol-
defined regimen was given to 346 patients, of whom
314 (83%) completed the full 48-week study (Fig. 2).
Overall, 32 of the 346 patients withdrew before
Week 48; the most common reasons for withdrawal
being lack of efficacy and withdrawal of consent
(10 patients each). Nine (2.6%) patients withdrew due
to AEs, which included acute respiratory distress
syndrome, bronchopneumonia, hypoxia, myocardial in-
farction, ovarian epithelial cancer, infusion-related reac-
tion (IRR) and sepsis.
Baseline characteristics and demography
Patient demographic and baseline disease characteristics
were well balanced across the three treatment groups
FIG.1Overview of study design.
Treatment period
RTX (2 × 500 mg) + MTX RTX (2 × 500 mg) + MTX
RTX (2 × 1000 mg) + MTX
RTX (2 × 1000 mg) + MTX
Second course First course
Randomization Primary end point ACR20 at Week 48
RTX (2 × 500 mg) + MTX
RTX (2 × 1000 mg) + MTX
Week 24
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Rituximab in RA patients with inadequate response to MTX(Table 1), and show that the recruited population had es-
tablished active disease (baseline DAS-28-ESR 6.7).
Baseline doses of MTX and use of oral corticosteroids
were similar across groups (Table 1) with doses remaining
stable during the course of the study. Patients had previ-
ously been treated with approximately two DMARDs, with
26% of patients in each group having previously
received a TNF inhibitor (Table 1).
Efficacy
At Week 48, ACR20 responses were achieved by 64,
64 and 72% of patients in the RTX 2500mg, dose es-
calation and RTX 21000mg groups, respectively (Fig. 3),
with there being no significant difference in ACR20 re-
sponse rates between dose groups. ACR50 and ACR70
responses were also similar between the treatment
groups. ACR response rates in the RTX 21000mg
group were somewhat higher than those in both the RTX
2500mg and dose escalation groups, although the dif-
ference was not statistically significant (Fig. 3). Analyses
conducted on the primary endpoint using the standard ITT
revealed results consistent with the mITT (ACR20 re-
sponses were achieved by 64, 65 and 68% of patients
in the RTX 2500mg, dose escalation and RTX
21000mg groups, respectively), with there being no sig-
nificant difference in ACR20 response rates between dose
groups [P=0.8864 (dose escalation vs 2500mg);
P=0.671 (21000 vs 2500mg)].
Moderate or good EULAR responses were achieved in
73, 72 and 89% of patients in the RTX 2500mg, dose
FIG.2Disposition of patients up to Week 48.
aFourteen patients were randomly assigned to rituximab (RTX) 21000mg,
placebo.
bSome patients received a treatment regimen other than that to which they were randomly assigned.
cSix
patients received placebo and 25 patients received RTX 2500mg for their second course (data on these 31 patients
treated with non-protocol-specified regimens not shown).
dOne patient did not receive a second course of treatment, but
completed 25 weeks of follow-up.
Patients displayed as randomly allocated
Reason for withdrawal, n (%)
AE or intercurrent illness 5 (3.7)
4 (3.0)
0
1 (0.7)
5 (3.7)
15 (11.2)
3 (2.5)
4 (3.3)
1 (0.8)
0
5 (4.2)
13 (10.9)
1 (1.1)
2 (2.2)
0
1 (1.1)
0
4 (4.3)
Insufficient therapeutic response
Failure to return
Violation of selection criteria at entry
Withdrew consent
Total
Patients displayed as treated
Treatedb
(first course)
Treated
(second course)
RTX 2 × 500mg
n =134
RTX 2 × 500mg
RTX 2 × 500mg
n =123
RTX 2 × 500mg
RTX 2 × 1000mg
n =128
RTX 2 × 1000mg
RTX 2 × 1000mg
n =127a
RTX 2 × 500mg
n =123
RTX 2 × 500mg
n =119
n =378
n =119 n =106 n =89d
RTX 2 × 1000mg
n =110
RTX 2 × 1000mg
n =124c
RTX 2 × 1000mg
n =88
Completed
48 weeks
Randomized
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Andrea Rubbert-Roth et al.escalation and RTX 21000mg groups, respectively (Fig.
4). EULAR responses were achieved by significantly more
patients in the rituximab 21000mg group compared
with the RTX 2500mg group (89 vs 73%, P=0.0495).
Although no significant differences in DAS remission were
observed between treatment groups, numerically higher
responses were seen in patients in the RTX 21000mg
group compared with RTX 2500mg and dose escalation
groups (19 vs 9 vs 13%, respectively; Fig. 4). Improvement
in disease activity, as indicated by a decrease from base-
line in mean DAS-28-ESR, was seen and maintained in all
groups over the 48-week period (Fig. 5). Following the
TABLE 1 Patient demographics and baseline disease characteristics
Characteristics
RTX
(2 x 500 and
2 x 500mg)+
MTX, n=134
RTX
(2 x 500 and
2 x 1000mg)+
MTX, n=119
RTX
(2 x 1000 and
2 x 1000mg)+
MTX, n=93
Demographics
Female, n (%) 110 (82.1) 90 (75.6) 77 (82.8)
Age, mean (S.D.), years 53.6 (12.8) 52.3 (12.1) 51.3 (12.2)
Duration of RA, mean (S.D.), years 9.0 (7.4) 9.6 (8.6) 7.7 (7.4)
Previous DMARDs,
a mean (S.D.), n 2.0 (1.5) 2.2 (1.6) 1.8 (1.4)
Earlier TNF inhibitor treatments, n (%) 37 (27.6) 31 (26.1) 23 (24.7)
MTX dose, mean (S.D.), mg/week 15.2 (4.7) 15.1
b (4.5) 15.2 (4.7)
Oral corticosteroid use, n (%) 85 (63.4) 78 (65.5) 63 (67.7)
NSAID use, n (%) 61 (45.5) 57 (47.9) 52 (55.9)
Disease characteristics
Mean SJC (66 joints) (S.D.), n 18.0 (9.0) 20.3 (10.5) 20.3 (10.5)
Mean TJC (68 joints) (S.D.), n 30.9 (13.7) 33.2 (14.1) 33.0 (14.3)
Mean baseline HAQ-DI (S.D.) 1.73 (0.7) 1.74
c (0.6) 1.61 (0.7)
RF
+, n (%) 95 (70.9) 87 (73.1) 64 (68.8)
RF
d, mean (S.D.), IU/ml 235.5 (416.6) 247.7 (416.1) 232.4 (366.1)
ESR, mean (S.D.), mm/h 46.7 (24.2) 47.7 (24.7) 45.2 (28.2)
CRP, mean (S.D.), mg/dl 2.1 (2.4) 2.6 (2.7) 2.2 (2.6)
DAS-28-ESR, mean (S.D.) 6.7
e (1.0) 6.8 (0.8) 6.7 (0.9)
aExcludes MTX.
bn=118.
cn=116.
d520IU/ml.
en=133.
FIG.3Number of patients achieving an improvement in ACR criteria at Week 48 (mITT population). *P=0.8156.
**P=0.2419 for RTX (2500 and 2500mg) vs RTX (2500mg, 21000mg) and RTX (21000 and 21000mg),
respectively.
RTX (2 × 500 mg, 2 × 500 mg) + MTX, n=134
RTX (2 × 500 mg, 2 × 1000 mg) + MTX, n =119
RTX (2 × 1000 mg, 2 × 1000 mg) + MTX, n=93
100
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64 64*
72**
39 39
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ments in mean DAS-28 were seen in all three treatment
groups (Fig. 5).
Mean improvements in the HAQ-DI were observed in all
three treatment groups between baseline and Week 48,
with no statistically significant differences between the
treatment groups (Table 2). Approximately 70% of pa-
tients in each of the treatment groups achieved the
MCID for HAQ-DI at Week 48.
All three treatment groups showed a similar improve-
ment in mean fatigue score relative to baseline at Week
48 (Table 2). At Week 48, 58, 64 and 69% of patients
achieved the MCID for FACIT-F in the RTX 2500mg,
dose escalation and RTX 21000mg groups, respectively
(Table 2).
All treatments were associated with positive improve-
ments in the mean physical health and mental health com-
ponent scores of the SF-36, with no statistically significant
difference between treatment groups (Table 2). The pro-
portion of patients achieving the MCID for mental compo-
nent and physical component summary scores at Week
48 was similar between all treatment groups, with higher
proportions achieving MCIDs for the physical component
summary score (Table 2).
In patients whose ACRn was <20 at Week 24 (i.e.
ACR20 non-responders), 44, 39 and 46% of patients in
the RTX 2500mg, dose escalation and RTX 21000mg
groups achieved at least an ACR20 at Week 48 following
their respective second treatment courses. Considering
patients who had an ACR response at Week 24, 78% of
patients receiving RTX 21000mg maintained or im-
proved their ACR response compared with 72 and 65%
in the dose escalation and RTX 2500mg groups, re-
spectively. Additionally, fewer patients (22%) receiving
RTX 21000mg had poorer response at Week 48 com-
pared with 28 and 35% in the dose escalation and RTX
2500mg groups, respectively (Table 3).
ACR20 response rates at Week 48 were similar in pa-
tients who had received an earlier biological treatment
(65%) compared with patients who were biological naı ¨ve
(67%). Similarly, ACR50, ACR70 and EULAR responses at
Week 48 were similar, regardless of an earlier biological
therapy. Within the earlier biological subgroup, response
rates for the RTX 21000mg group were consistently
higher than those of the RTX 2500mg group. For ex-
ample, higher proportions of patients achieved ACR50 (52
vs 33%), ACR70 (24 vs 18%) and EULAR good or mod-
erate responses (88 vs 73%) in the RTX 21000mg than
the RTX 2500mg group. However, patient numbers
within this subgroup were small and the difference in pro-
portions between treatment groups was not statistically
significant.
Pharmacodynamics
Peripheral B-cell levels were fully depleted after the first
course of RTX, with no clear difference in peripheral
CD19
+ B-cell depletion and repletion profiles between
the treatment groups over 48 weeks. Median CD19
+
B-cell counts of 9–15cells/ml at 24 weeks and 5–7cells/
ml at 48 weeks were observed. Mean levels of peripheral
T cells (CD3) and T-cell subsets (CD4
+ and CD8
+)
remained stable through Week 48 in all three treatment
arms, as did memory (CD3
+, CD4
+ CD45Ro
+/CD45Ra
),
FIG.4Summary of clinical efficacy at Week 48.
aDAS-28-ESR <2.6. *P=0.0495 for RTX (2500 and 2500mg) vs
RTX (2500 and 21000mg). LDA: low disease activity.
RTX (2 × 500 mg, 2 × 500 mg) + MTX, n=134
RTX (2 × 500 mg, 2 × 1000 mg) + MTX, n=119
RTX (2 × 1000 mg, 2 × 1000 mg) + MTX, n=93
100
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+, CD4
+ CD45Ro
/CD45Ra
+) and transitional
(CD3
+, CD4
+ CD45Ro
+/CD45Ra
+) subsets.
Following the first treatment course, mean IgA, IgG, IgM
and total Ig concentrations declined from baseline levels
in all groups, stabilizing between Weeks 8 and 24.
Following the second treatment course, mean Ig concen-
trations underwent a further decline; however, mean con-
centrations of all isotypes remained within normal limits at
all time points up to Week 48. At Week 48, <1% of
patients had a total Ig concentration below the lower
limit of normal. IgG concentrations were below normal
in 1.7, 0 and 0% of patients in the 2500mg, dose
escalation and 21000mg groups, respectively. Higher
proportions of patients had IgM concentrations below
normal limits (13.7, 13.3 and 10.1%, respectively).
Levels of RF (including RF isotypes) and aCCP were
reduced by 45% in all three treatment groups by
Week 48.
FIG.5Plot of mean change from baseline in DAS-28-ESR score by visit, last observation carried forward (LOCF)
imputation (mITT population).
RTX (2 × 500 mg, 2 × 500 mg) + MTX, n=134
RTX (2 × 500 mg, 2 × 1000 mg) + MTX, n=119
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TABLE 2 Summary of patient-reported outcomes at Week 48
Outcomes
RTX
(2 x 500 and
2 x 500mg)+
MTX
RTX
(2 x 500 and
2 x 1000mg)+
MTX
RTX
(2 x 1000 and
2 x 1000mg)+
MTX
HAQ-DI, n 134 115 93
Change from baseline score (LOCF), mean (S.D.)
a 0.5 (0.6) 0.6 (0.6) 0.6 (0.6)
Patients with MCID, n (%)
b 93 (69.4) 86 (72.3)
c 67 (72.0)
FACIT-F, n 125 115 91
Change from baseline (LOCF), mean (S.D.)
d 6.6 (10.2) 8.1 (10.3) 8.4 (9.8)
Patients with MCID from baseline, n (%)
e 72 (57.6) 74 (64.3) 63 (69.2)
SF-36
Mean change from baseline (LOCF), n 121 112 87
Change in mental health score, mean (S.D.) 5.6 (12.4) 5.0 (11.8) 4.7 (11.1)
Change in physical health score, mean (S.D.) 7.2 (8.5) 7.2 (8.3) 9.0 (9.7)
SF-36
Mental component summary, n 134 118 93
Patients with improved summary score, n (%)
f 58 (43.3) 48 (40.7) 37 (39.8)
SF-36
Physical component summary, n 134 118 93
Patients with improved summary score, n (%)
g 69 (51.5) 66 (55.9) 53 (57.0)
aA negative change from baseline indicates an improvement.
bHAQ-DI score decrease >0.22.
cn=119.
dPositive change from
baseline indicates an improvement.
eChange from baseline 54.
fSF-36 score change >6.33.
gSF-36 score change >5.42.
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Rituximab in RA patients with inadequate response to MTXAt Week 24, the incidence of positive HACA titres was
5.1, 7.3 and 2.3% in the RTX 2500mg, dose escalation
and RTX 21000mg groups, respectively, although this
declined to 4.3, 1.0 and 2.3%, respectively, by Week 48.
In total, 18.8% (3/16) of HACA-positive patients at Week
24 following the first course experienced an IRR during the
second exposure to RTX, which is consistent with the
overall incidence of IRRs during the second course
(17%). The presence of HACAs did not appear to influ-
ence either the ability of RTX to deplete CD19
+ B cells or
efficacy or safety outcomes.
Safety
The incidence of AEs, SAEs and AEs leading to with-
drawal (RA flares excluded) was similar across treatment
groups (Table 4). Common AEs included RA flares, naso-
pharyngitis and upper respiratory tract infections and
IRRs. IRRs were reported in 39, 30 and 30% of patients
in the RTX 2500mg, dose escalation and RTX
21000mg groups, respectively, with the incidence
being higher following the first course than following the
second course (Table 4). Two patients (both in the RTX
2500mg group) experienced a serious IRR during the
first infusion of the first course, with three further patients
experiencing IRRs that were CTC AE Grade 3 events.
Multiple symptoms were reported for each IRR and
included angioneurotic oedema, bronchospasm, flushing,
hypotension, laryngeal or pharyngeal oedema, throat irri-
tation, pruritus and pyrexia.
Approximately 60% of patients experienced at least
one infection during the study period. The most frequently
reported infections included nasopharyngitis, upper and
lower respiratory tract infections (including bronchitis)
and urinary tract infections. A total of 11 serious infections
were reported, including sepsis, skin ulcer, lower respira-
tory tract infection and sinusitis in the RTX 2500mg
group; bronchopneumonia, respiratory tract infection,
post-operative wound infection, gastroenteritis and bron-
chitis in the dose escalation group; and diverticulitis and
acute pyelonephritis in the RTX 21000mg group. The
rate of all infections and serious infections per 100
patient-years over 48 weeks was similar across treatment
groups (Table 4) and no opportunistic infections were re-
ported during the study period. There was no apparent
association between the occurrence of a serious infection
and low Ig levels. Indeed, in 9 of 11 cases of serious in-
fection, the patients had Ig concentrations (total and iso-
type) within the normal range. Two serious infections
(bronchitis and diverticulitis) were reported in patients
who developed low IgM levels following RTX treatment,
although all other isotypes remained within the normal
range.
Malignancies were reported in four (1.2%) patients, and
included basal cell carcinoma (one case each in RTX
2500mg and dose escalation groups), squamous cell
carcinoma of the skin (dose escalation group) and
Hodgkin’s disease (RTX 21000mg group).
Discussion
The objective of this study was to determine the impact of
various repeat treatment regimens with RTX, either at the
same dose (two courses of 2500mg 24 weeks apart) or
at a higher dose (dose escalation, 2500mg followed by
retreatment with 21000mg). In addition, the standard
regimen of two courses of 21000mg 24 weeks apart
was evaluated. With respect to the primary endpoint
(ACR20 at Week 48), there were no statistically significant
differences between the three treatment regimens.
Although the power of the study to detect dose differ-
ences was somewhat compromised by the treatment
errors that occurred, analyses based on the ITT popula-
tion ‘as randomized’ or ‘as treated’ (presented in this art-
icle), were consistent with each other.
RTX was found to be an effective treatment in patients
with an inadequate response to MTX, with some important
and relevant clinical observations being made. ACR re-
sponse rates across the treatment groups at Week 48
were comparable with those previously reported with
RTX [1] and also with those reported for biological
agents [17–20], albeit with the caveat that in this study
there was no control group for comparison. Importantly,
high-hurdle disease activity endpoints, such as ACR70,
DAS low disease activity or remission at Week 48, were
TABLE 3 Summary of shift in ACR response from Week 24 to Week 48
ACRn
category at
Week 24
Week 24–48
shift in response
RTX
(2 x 500 and
2 x 500mg)+
MTX, n=134
RTX
(2 x 500 and
2 x 1000mg)+
MTX, n=119
RTX
(2 x 1000 and
2 x 1000mg)+
MTX, n=93
<ACR20 (NR) N 59 44 28
Improved,
a n (%) 26 (44) 17 (39) 13 (46)
Remained in NR category, n (%) 33 (56) 27 (61) 15 (54)
>ACR20 N 75 74 65
Improved,
a n (%) 28 (37) 26 (35) 18 (28)
Maintained,
b n (%) 21 (28) 27 (36) 33 (51)
Worsened,
c n (%) 26 (35) 21 (28) 14 (22)
aShift upwards by at least one category.
bRemained in the same category of ACR response.
cShift downwards by at least one
category. NR: non-response.
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sults of a previous study in patients with active RA resist-
ant to DMARDs [1].
Secondary endpoints broadly supported the primary
outcome; however, there was an indication that patients
receiving RTX 21000mg in each treatment course
achieved better responses. For example, the proportion
of patients achieving remission in the RTX 21000mg
group was twice that in the RTX 2500mg group (9 vs
19%, respectively). Similarly, significantly more patients in
the RTX 21000mg group achieved a EULAR good or
moderate response compared with the RTX 2500mg
group (89 vs 73%, respectively). Supporting these obser-
vations, higher proportions of patients in the RTX
21000mg group maintained their Week 24 ACR re-
sponse category compared with those in the dose escal-
ation and RTX 2500mg groups. Indeed, 78% of patients
in the RTX 21000mg group who achieved an ACR20 at
Week 24 maintained or improved their ACR response cat-
egory at Week 48. In contrast, 65% of patients initially
receiving RTX 2500mg maintained or improved their re-
sponse following a further course of the same lower dose.
The study has also provided insight into the effect of
repeat treatment in patients who had not achieved an
ACR20 at Week 24. In a recent study, retreatment with
RTX in patients who had not achieved a EULAR response
on two consecutive visits following an initial course re-
sulted in continued non-response [21], indicating that fur-
ther treatment of non-responding patients may not be
beneficial. However, in this study, of 131 patients across
all groups who were ACR non-responders at Week 24,
43% achieved at least an ACR20 response at Week 48
following repeat treatment.
This study is also the first study where a second course
of RTX was given at a fixed time interval (24 weeks) fol-
lowing the initial treatment. Repeat treatments in previ-
ously reported studies have been given based on clinical
symptoms, together with the physicians’ decision to give
further courses. As a consequence, time intervals be-
tween courses were prolonged (33 weeks), with pa-
tients’ disease activity returning close to pre-treatment
levels before each course [5]. In contrast, the strategy of
administering two courses of RTX 24 weeks apart in the
current study appeared to induce a sustained decrease in
disease activity over time, as illustrated by maintained or
improved outcomes in DAS-28 following the 24-week
repeat treatment. This fixed repeat treatment approach
would, therefore, appear to be more beneficial than
TABLE 4 Summary of safety profile over 48 weeks
RTX
(2 x 500mg,
2 x 500mg)+MTX,
n=134
RTX
(2 x 500mg,
2 x 1000mg)+MTX,
n=119
RTX
(2 x 1000mg,
2 x 1000mg)+MTX,
n=93
Treated first course, n 134 119 93
Treated second course, n 123 110 88
Patient-years of observation 119.2 105.8 84.8
AEs, n (%)
Any AE 121 (90) 106 (89) 85 (91)
SAE 15 (11) 21 (18) 16 (17)
AE leading to withdrawal
a 5 (4) 8 (7) 3 (3)
Death 0 (0) 0 (0) 0 (0)
IRR, n (%)
Any IRR 52 (39) 36 (30) 28 (30)
First course
Any 44 (33) 27 (23) 25 (27)
Serious and/or CTC AE Grade 3 4 (3.0) 0 (0) 0 (0)
Second course
b
Any 22 (18) 16 (15) 17 (19)
Serious and/or CTC AE Grade 3 0 (0) 1 (<1) 0 (0)
Malignancy
Any 1 (<1) 2 (2) 1 (1)
Serious 0 (0) 1 (<1) 1 (1)
Infection
Any 75 (56) 73 (61) 60 (65)
Serious
c 4 (3) 4 (3) 2 (2)
Total infections, n 144 150 135
Infections per 100 patient-years (95% CI) 120.8 (102.6, 142.2) 141.8 (120.9, 166.4) 159.2 (134.5, 188.4)
Total serious infections, n 452
Serious infections
c per 100 patient-years (95% CI) 3.4 (1.3, 8.9) 4.7 (2.0, 11.4) 2.4 (0.6, 9.4)
aIncludes five patients with events of RA flare (primary reason for withdrawal was lack of efficacy and two patients who
withdrew for AEs whose day of withdrawal was not available on the database at data cut-off.
bPercentage based on no
treated second course.
cReported as serious and/or treated with intravenous antibiotics. GI: gastrointestinal.
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retreatment. These observations are also supported by
recent data indicating that clinical responses were better
maintained in patients receiving 24-week treatment
courses based on their DAS-28 [22]. Longer term
follow-up of both efficacy and safety of rituximab using
such repeat treatment regimens is therefore clearly
warranted.
The efficacy of rituximab was apparent irrespective of
whether patients had received prior treatment with a TNF
inhibitor, with patients who had received prior TNF inhibi-
tors deriving as much benefit from RTX treatment as the
overall population. Patients in the earlier biological therapy
subgroup receiving RTX 21000mg tended to have con-
sistently higher ACR and EULAR outcomes compared
with those in the RTX 2500mg group. However, these
data should be interpreted with caution, as patient num-
bers in this earlier biological subgroup were small and no
statistically significant difference was found between the
dose regimens.
The safety profile of rituximab reported in this study was
consistent with previous experience, including that of re-
peated courses, with no new or unexpected safety signals
being observed [3–5, 23]. The rates of AEs were similar
across treatment groups and were primarily characterized
by IRRs and infections, experienced by 34 and 60% of
patients, respectively. Clinically significant (serious or
CTC AE grade 53) infusion reactions were uncommon
(five events, 3%); however, these led to discontinuation
in two patients. Such events were predominately observed
in the 2500mg dose group and were associated with the
first infusion of the first treatment course. The rate of ser-
ious infections was lower than that observed in previously
published studies (overall 3.36 compared with 4.7–5.2
events per 100 patient-years) [3, 24, 25]. Importantly,
there was no association between the incidence of serious
infection and the presence of low Ig (including Ig isotypes).
Other events of interest included malignancies, the inci-
dence of which was also comparable with that reported
in 1039 RA patients treated with RTX [5].
In conclusion, these data support RTX as an effective
and well-tolerated therapy in patients with RA and an in-
adequate response to DMARDs, irrespective of the earlier
treatment with a TNF inhibitor. Although RTX doses and
retreatment regimens could not be clearly differentiated,
several efficacy outcomes favoured treatment with RTX
21000mg. Repeat treatment at Week 24 with RTX main-
tained the response achieved with the first course and
may be associated with improved efficacy outcomes.
The safety profile of RTX remained favourable, with no
new safety signals becoming apparent with repeat
courses.
Rheumatology key messages
. RTX is effective and well tolerated in patients with
an inadequate response to DMARDs.
. Some efficacy outcomes suggest improved out-
comes for RTX 21000 vs 2500mg.
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